{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T20:49:43Z","timestamp":1740170983979,"version":"3.37.3"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"MSD"},{"DOI":"10.13039\/501100004948","name":"Astellas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Pfizer and Novartis"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.jgar.2018.06.009","type":"journal-article","created":{"date-parts":[[2018,6,30]],"date-time":"2018-06-30T12:40:30Z","timestamp":1530362430000},"page":"82-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Micafungin use in a UK tertiary referral hospital"],"prefix":"10.1016","volume":"15","author":[{"given":"David A.","family":"Enoch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christianne","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huina","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas M.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sani H.","family":"Aliyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2018.06.009_bib0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40262-017-0578-5","article-title":"Clinical pharmacokinetics and pharmacodynamics of micafungin","volume":"57","author":"Wasmann","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jgar.2018.06.009_bib0010","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jinf.2014.01.007","article-title":"Micafungin for the treatment of invasive aspergillosis","volume":"68","author":"Enoch","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2018.06.009_bib0015","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/jac\/dkp355","article-title":"An EORTC phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients","volume":"64","author":"Viscoli","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2018.06.009_bib0020","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1093\/jac\/dkv040","article-title":"Introduction of an antifungal stewardship programme targeting high-cost antifungals at a tertiary hospital in Cambridge, England","volume":"70","author":"Micallef","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2018.06.009_bib0025","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2018.06.009_bib0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-1-4939-6515-1_2","article-title":"The changing epidemiology of invasive fungal infections","volume":"1508","author":"Enoch","year":"2017","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jgar.2018.06.009_bib0035","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1099\/jmm.0.000612","article-title":"An investigation of antifungal stewardship programmes in England","volume":"66","author":"Micallef","year":"2017","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.jgar.2018.06.009_bib0040","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ1194","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2018.06.009_bib0045","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jinf.2016.01.008","article-title":"Impact of a candidaemia care bundle on patient care at a large teaching hospital in England","volume":"72","author":"Gouliouris","year":"2016","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2018.06.009_bib0050","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1186\/s12879-014-0725-7","article-title":"Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study","volume":"14","author":"Viscoli","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2018.06.009_bib0055","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/00365540410020406","article-title":"A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan","volume":"36","author":"Kohno","year":"2004","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jgar.2018.06.009_bib0060","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s10156-011-0219-0","article-title":"Evaluation of the safety and efficacy of micafungin in Japanese patients with deep mycosis: a post-marketing survey report","volume":"17","author":"Hanadate","year":"2011","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jgar.2018.06.009_bib0065","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10096-012-1754-z","article-title":"A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis","volume":"32","author":"Kohno","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2018.06.009_bib0070","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1128\/AAC.00051-14","article-title":"Efficacy and tolerability of micafungin monotherapy for candidemia and deep-seated candidiasis in adults with cancer","volume":"58","author":"Farmakiotis","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.06.009_bib0075","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jinf.2006.03.003","article-title":"Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis","volume":"53","author":"Denning","year":"2006","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2018.06.009_bib0080","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1399-3062.2008.00349.x","article-title":"Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis","volume":"11","author":"Kontoyiannis","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jgar.2018.06.009_bib0085","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/ajh.21858","article-title":"Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies","volume":"85","author":"Goto","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jgar.2018.06.009_bib0090","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00277-011-1277-1","article-title":"Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study","volume":"90","author":"Yamaguchi","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jgar.2018.06.009_bib0095","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/cid\/ciu1128","article-title":"Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients","volume":"60","author":"Saliba","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2018.06.009_bib0100","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.medmal.2016.03.008","article-title":"Micafungin as primary antifungal prophylaxis in patients presenting with acute myeloid leukemia","volume":"46","author":"Venton","year":"2016","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.jgar.2018.06.009_bib0105","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1093\/jac\/dkw225","article-title":"Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study","volume":"71","author":"Schneeweiss","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 6","key":"10.1016\/j.jgar.2018.06.009_bib0110","doi-asserted-by":"crossref","first-page":"S652","DOI":"10.1093\/cid\/civ818","article-title":"Safety and efficacy of intermittent intravenous administration of high-dose micafungin","volume":"61","author":"Neofytos","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2018.06.009_bib0115","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2018.06.009_bib0120","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.clinthera.2010.04.005","article-title":"Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis","volume":"32","author":"Kubiak","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.jgar.2018.06.009_bib0125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.resinv.2013.07.001","article-title":"Scedosporium aurantiacum brain abscess after near-drowning in a survivor of a tsunami in Japan","volume":"51","author":"Nakamura","year":"2013","journal-title":"Respir Investig"},{"key":"10.1016\/j.jgar.2018.06.009_bib0130","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10156-008-0657-5","article-title":"Breakthrough disseminated zygomycosis induced massive gastrointestinal bleeding in a patient with acute myeloid leukemia receiving micafungin","volume":"15","author":"Suzuki","year":"2009","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jgar.2018.06.009_bib0135","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jiac.2013.09.006","article-title":"Infective endocarditis and meningitis due to Scedosporium prolificans in a renal transplant recipient","volume":"20","author":"Uno","year":"2014","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jgar.2018.06.009_bib0140","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/ejh.12426","article-title":"Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study","volume":"94","author":"Nachbaur","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jgar.2018.06.009_bib0145","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.idcr.2018.03.017","article-title":"Fatal breakthrough mucormycosis in a multivisceral transplant patient receiving micafungin: case report and literature review","volume":"12","author":"Louis-Auguste","year":"2018","journal-title":"IDCases"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221371651830119X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221371651830119X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T20:23:39Z","timestamp":1661545419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221371651830119X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":29,"alternative-id":["S221371651830119X"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2018.06.009","relation":{},"ISSN":["2213-7165"],"issn-type":[{"type":"print","value":"2213-7165"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Micafungin use in a UK tertiary referral hospital","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2018.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}